Volume 14, Number 10—October 2008
Research
Prophylaxis after Exposure to Coxiella burnetii
Claire E. Moodie
, Herbert A. Thompson, Martin I. Meltzer, and David L. Swerdlow
, Herbert A. Thompson, Martin I. Meltzer, and David L. Swerdlow
Figure 2
![Decision tree for a high-risk population of 100,000 based on an assumption of an aerosolized, point source, overt attack with Coxiella burnetii (postexposure prophylaxis [PEP] with 100 mg doxycycline 2×/d for 5 d, assuming 82% drug efficacy and 100% exposure). PEP-related adverse events are not included in this figure. QFS, Q fever fatigue syndrome.](/eid/images/08-0576-F2.jpg)
Figure 2. Decision tree for a high-risk population of 100,000 based on an assumption of an aerosolized, point source, overt attack with Coxiella burnetii (postexposure prophylaxis [PEP] with 100 mg doxycycline 2×/d for 5 d, assuming 82% drug efficacy and 100% exposure). PEP-related adverse events are not included in this figure. QFS, Q fever fatigue syndrome.
Page created: July 13, 2010
Page updated: July 13, 2010
Page reviewed: July 13, 2010
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.